Ionis’ HAE Opportunity Boosted By Positive Phase II Data
Wholly Owned PKK-LRx HAE Candidate Hit All Endpoints
Positive topline Phase II data for Ionis’ antisense hereditary angioedema candidate has boosted the biotech’s chances of developing PKK-LRx as a treatment for the disease.
